EGFR and non-small cell lung carcinoma: There are currently clinical trials underway focused on the use of PI3K/Akt inhibitors to improve patient outcomes following developed resistance to anticancer therapies such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors [5,47] (reviewed in [48]) which represent a first line of treatment for NSCLC patients.